Thomas Steyer Farallon Capital Management
Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boston Scientific
BSX
|
+$166M |
| 2 |
Roivant Sciences
ROIV
|
+$137M |
| 3 |
Immunovant
IMVT
|
+$130M |
| 4 |
BridgeBio Pharma
BBIO
|
+$96.5M |
| 5 |
Baidu
BIDU
|
+$94.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$498M |
| 2 |
Amazon
AMZN
|
+$398M |
| 3 |
Charles Schwab
SCHW
|
+$372M |
| 4 |
Aon
AON
|
+$365M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$286M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 54.84% |
| 2 | Miscellaneous | 21.83% |
| 3 | Communication Services | 8.41% |
| 4 | Technology | 5.7% |
| 5 | Financials | 3.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
AleAnna Inc
ANNA
$96.2M
| $227K | ﹤0.01% |
78,400
| – | – |
2024 Q4
6 quarters
|
|
77
Welltower
WELL
$169B
| $227K | ﹤0.01% |
1,000
-199,000
| -100% | -$42.1M |
2025 Q4
2 quarters
|
|
78
Solid Power Inc Warrant
SLDPW
$3.25M
| $41.4K | ﹤0.01% |
405,316
| – | – |
2021 Q4
18 quarters
|
|
79
Blue Gold Ltd Warrant
BGLWW
$293K
| $30.7K | ﹤0.01% |
255,800
-44,200
| -15% | -$9.5K |
2025 Q3
3 quarters
|
|
80
Pacific Biosciences
PACB
$662M
| $23.9K | ﹤0.01% |
14,200
-120,800
| -89% | -$176K |
2022 Q4
14 quarters
|
|
81
Geron
GERN
$732M
| $18.4K | ﹤0.01% |
14,400
-28,600
| -67% | -$40.3K |
2024 Q1
9 quarters
|
|
82
DELISTED
Nvni Group Limited Warrants
NVNIW
| $17.6K | ﹤0.01% |
375,000
| – | – |
2023 Q4
10 quarters
|
|
83
Canopy Growth
CGC
$284M
| $17.1K | ﹤0.01% |
18,000
-12,000
| -40% | -$12.7K |
2024 Q2
8 quarters
|
|
84
Rani Therapeutics
RANI
$69.9M
| $15.7K | ﹤0.01% |
20,700
-57,300
| -73% | -$50.8K |
2025 Q4
2 quarters
|
|
85
Beyond Meat
BYND
$117M
| $14.2K | ﹤0.01% |
633
| – | – |
2025 Q2
4 quarters
|
|
86
Adaptive Biotechnologies
ADPT
$4.05B
| – | – |
-11,000
| Closed | -$153K | – |
|
87
Affirm
AFRM
$24.8B
| – | – |
-108,000
| Closed | -$4.95M | – |
|
88
AAR Corp
AIR
$4B
| – | – |
-46,000
| Closed | -$5.04M | – |
|
89
Alkermes
ALKS
$7.3B
| – | – |
-20,800
| Closed | -$735K | – |
|
90
Altimmune
ALT
$434M
| – | – |
-27,600
| Closed | -$85K | – |
|
91
Amkor Technology
AMKR
$10.9B
| – | – |
-104,000
| Closed | -$4.68M | – |
|
92
DELISTED
Apellis Pharmaceuticals
APLS
| – | – |
-6,000
| Closed | -$241K | – |
|
93
Ardelyx
ARDX
$808M
| – | – |
-23,000
| Closed | -$138K | – |
|
94
Arcutis Biotherapeutics
ARQT
$4.01B
| – | – |
-26,000
| Closed | -$613K | – |
|
95
Arrowhead Research
ARWR
$8.33B
| – | – |
-15,800
| Closed | -$991K | – |
|
96
Axsome Therapeutics
AXSM
$8.18B
| – | – |
-4,000
| Closed | -$676K | – |
|
97
BioCryst Pharmaceuticals
BCRX
$1.98B
| – | – |
-24,000
| Closed | -$228K | – |
|
98
Belite Bio
BLTE
$6.17B
| – | – |
-1,300
| Closed | -$207K | – |
|
99
Citigroup
C
$208B
| – | – |
-47,000
| Closed | -$5.33M | – |
|
100
Cardinal Health
CAH
$59.6B
| – | – |
-368,000
| Closed | -$77.8M | – |
|
Similar funds
Thomas Steyer's Q2 2026 Portfolio in Review
As of Q2 2026, Thomas Steyer held 194 positions worth $21.7B, up 14% from $19.1B the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Thomas Steyer withdrew a net $3.46B in Q2 2026, closing 105 positions and reducing 23 holdings. Its most notable exit was Charles Schwab, an estimated $372M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 55% of assets, up from 47% a quarter earlier, followed by Miscellaneous and Communication Services.
Against the trend, Thomas Steyer opened a new position in Parabilis Medicines Inc worth $64.8M.
- Thomas Steyer's largest Q2 2026 buy was Parabilis Medicines Inc: 2,368,200 shares worth $64.8M.
- Thomas Steyer added most to Boston Scientific in Q2 2026, an estimated $166M increase.
- Thomas Steyer's biggest Q2 2026 reduction was Microsoft, cutting an estimated $498M.
- Thomas Steyer fully exited Charles Schwab in Q2 2026, selling an estimated $372M.
- Thomas Steyer's ten largest holdings make up 62% of its $21.7B portfolio in Q2 2026.
- Thomas Steyer opened 19 new positions and closed 105 in Q2 2026.
- Thomas Steyer's portfolio value rose 14% quarter-over-quarter to $21.7B.
Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.